Olmetec and Protein - urine - a phase IV clinical study of FDA data

Summary:

Protein - urine is reported as a side effect among people who take Olmetec (olmesartan medoxomil), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Lipitor, and have Lupus nephritis.

The phase IV clinical study analyzes which people have Protein - urine when taking Olmetec. It is created by eHealthMe based on reports of 7,816 people who have side effects when taking Olmetec from the FDA, and is updated regularly.

What is Olmetec?

Olmetec has active ingredients of olmesartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 7,904 Olmetec users. Check the latest studies of Olmetec.

What is Protein - urine?

Protein - urine is found to be associated with 1,565 drugs and 2,011 conditions by eHealthMe. Check the latest studies of Protein - urine.

On Jul, 20, 2026

7,816 people reported to have side effects when taking Olmetec.
Among them, 22 people (0.28%) have Protein - urine.

Among these 22 people:

How long have people been on Olmetec when they have Protein - urine? *

What is the gender of people who have Protein - urine when taking Olmetec? *

female: 73.68 %
male: 26.32 %

What is the age of people who have Protein - urine when taking Olmetec? *

What are other drugs people take besides Olmetec? *

What are other side effects people have besides Protein - urine? *

Hypokalemia (low potassium): 6 people, 27.27%
Haematuria (presence of blood in urine): 5 people, 22.73%
Oedema Peripheral (superficial swelling): 5 people, 22.73%
Urinary Casts: 4 people, 18.18%
Type 2 Diabetes: 4 people, 18.18%
Diarrhea: 4 people, 18.18%
Hypoalbuminaemia (levels of albumin in blood serum are abnormally low): 4 people, 18.18%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 4 people, 18.18%
Nausea And Vomiting: 3 people, 13.64%
Renal Impairment (severely reduced kidney function): 3 people, 13.64%

What are the existing conditions these people have? *

Type 2 Diabetes: 4 people, 18.18%
Lupus Nephritis (a chronic inflammatory autoimmune disorder that may affect kidney tissue): 4 people, 18.18%
Hepatocellular Carcinoma (liver cancer): 3 people, 13.64%
High Blood Cholesterol: 3 people, 13.64%
Thyroid Cancer: 3 people, 13.64%
Multiple Myeloma (cancer of the plasma cells): 2 people, 9.09%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 9.09%
Oedema (fluid collection in tissue): 2 people, 9.09%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 1 person, 4.55%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 1 person, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Olmetec and have Protein - urine?

- Check whether Protein - urine is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Olmetec:

Olmetec (7,904 reports)

Protein - urine treatments and more:

Protein - urine (24,757 reports)

Browse all side effects of Olmetec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Protein - urine:

Protein - urine (1,565 drugs)

Browse all the conditions that are associated with Protein - urine:

Protein - urine (2,011 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on olmesartan medoxomil (the active ingredients of Olmetec) and Olmetec (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.